The difficulty of detecting lung cancer at an early stage, its aggressiveness, the lack of effective systemic therapy, and the rapid development of resistance to chemotherapeutics are responsible for its high mortality. There is an urgent need for novel therapeutic strategies for the efficient treatment of lung cancer and new ways to overcome drug resistance. New treatments designed to restore functions of defective genes and gene products in tumor suppressing and apoptotic pathways by gene transfer and to target specific and frequently occurring molecular alterations in key signaling pathways by """"""""smart drugs,"""""""" such as protein tyrosine kinase (PTK) inhibitors, are fundamentally changing cancer therapy and hold promise for lung cancer treatment. Our goal is to develop an integrated therapeutic strategy for malignant lung cancer and metastases by combining a systemic and tumor-selective molecular therapy using DOTAP:Cholesterol-DNA nanoparticles with the novel multifunctional tumor suppressor gene FUS1 driven by a chimeric hTERT-mini-CMV (hTMC) promoter to directly activate the apoptotic pathway, a chemotherapy strategy using small molecule PTK inhibitors to specifically target the oncogenic PTK-mediated signaling pathway, and an innovative, noninvasive molecular imaging technique using an hTMC-SSRT2A-FUS1 vector system with magnetic resonance imaging and gamma-camera imaging to monitor the expression and anticancer efficacy of the therapeutic gene. This goal will be achieved via these Specific Aims: 1) evaluating the therapeutic efficacy of systemic administration of hTMC-FUS1 nanoparticles in human lung cancer mouse models;2) evaluating the therapeutic efficacy of treatment with FUS1 nanoparticles and novel small molecule PTK inhibitors erlotinib and imatinib in vitro and in vivo to enhance efficacy and overcome drug resistance in lung cancer;3) analyzing the interactions of the Fus1 protein with its cellular targets in tumor suppressing, apoptotic, and PTK signaling pathways to reveal the molecular mechanisms of FUS1-mediated tumor suppression and identify potential therapeutic targets;and 4) developing noninvasive molecular imaging technologies in mice for monitoring gene expression and biodistribution using the hTMC-FUS1-SSRT2A dual reporter and therapeutic gene expression system by gamma-camera imaging and for evaluation of the systemic therapeutic efficacy of FUS1-nanoparticles by magnetic resonance imaging analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA116322-04
Application #
7800291
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Forry, Suzanne L
Project Start
2007-06-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
4
Fiscal Year
2010
Total Cost
$292,600
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Lara-Guerra, Humberto; Roth, Jack A (2016) Gene Therapy for Lung Cancer. Crit Rev Oncog 21:115-24
Lin, Jing; Xu, Kai; Roth, Jack A et al. (2016) Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis. Biochem Biophys Rep 6:16-23
Xu, Kai; Lin, Jing; Zandi, Roza et al. (2016) MicroRNA-mediated target mRNA cleavage and 3'-uridylation in human cells. Sci Rep 6:30242
Lin, Jing; Xu, Kai; Wei, Jun et al. (2016) MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer. J Gene Ther 2:
Dai, Bingbing; Yan, Shaoyu; Lara-Guerra, Humberto et al. (2015) Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS One 10:e0123967
Han, Lin; Ravoori, Murali; Wu, Guanglin et al. (2013) Somatostatin receptor type 2-based reporter expression after plasmid-based in vivo gene delivery to non-small cell lung cancer. Mol Imaging 12:1-10
Huschka, Ryan; Barhoumi, Aoune; Liu, Qing et al. (2012) Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano 6:7681-91
Jayachandran, Gitanjali; Roth, Jack A; Ji, Lin (2012) Analysis of protein-protein interaction using proteinchip array-based SELDI-TOF mass spectrometry. Methods Mol Biol 818:217-26
Ji, Lin; Jayachandran, Gitanjali; Roth, Jack A (2012) High throughput profiling of serum phosphoproteins/peptides using the SELDI-TOF-MS platform. Methods Mol Biol 818:199-216
Lin, Jing; Xu, Kai; Gitanjali, Jayachandran et al. (2011) Regulation of tumor suppressor gene FUS1 expression by the untranslated regions of mRNA in human lung cancer cells. Biochem Biophys Res Commun 410:235-41

Showing the most recent 10 out of 16 publications